Interview, Fireside Chat
Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX
- AI is expected to accelerate drug discovery and transform the entire value chain from lab development to commercialization, with a projected shift in bottlenecks from discovery to manufacturing.
- Drug development timelines could shorten from 10 years to 4 years if success rates improve significantly, specifically rising from 5% to 60%, while new drugs may emerge every three years rather than every decade.
- Achieving 88% to 90% success rates in processes currently facing over 90% failure will require advancements in molecular design and testing, with entities like Isomorphic Labs extending work beyond protein folding.
- Clinical trial phases are projected to become a system-wide optimization effort driven by agencies like ARPA-H to prevent bottlenecks and improve efficiency.
- Customized "N of 1" and "end-of-one" medicine will become more scalable and repeatable, though the cost to develop and deliver these treatments must be significantly reduced.
- Neuralink aims to vertically integrate its supply chain, including pathology labs, while expanding functionality for paralysis, ALS, and limb usage, with future goals to enable speech via vocal cortex implants.
- Hearing loss is anticipated to rise globally due to headphone usage, driving increased demand for Fortel hearing aids and an expected disappearance of waitlists as production ramps up.
- Healthcare is projected to remain the largest job engine, accounting for 30% of new jobs, with US spending growing from $5 trillion to $9 trillion by the end of the decade.
- Life expectancy in the US is forecasted to rise from approximately 80 years to 100 years over the next 10 years, driven by scientific advancements and increased societal resource allocation toward longevity.
- The macro trends of AI and AGI are predicted to spur the emergence of more trillion-dollar healthcare companies and increased spending on health and longevity.
- Companies like Cadence are expected to continue reducing hospitalizations by 25% and increasing blood pressure control to over 80%, leveraging AI agents that have already boosted patient engagement by 70%.
- Legacy incumbents such as Lilly, McKesson, and health systems are expected to aggressively acquire or build AI capabilities, with large distributors purchasing care delivery assets and new companies IPOing or being acquired.
- OpenAI's ChatGPT is projected to serve as a primary healthcare resource for 300 million weekly queries, enabling self-treatment and optimizing surgeon schedules to reduce orthopedic wait times from three to one month.
- Future systems will prioritize a "10x nurse" over a "10x engineer" to leverage new tools effectively, while AI helps equalize access to care between rural areas and major cities.
- New trends in medicine will provide customized treatments for previously untreatable conditions, building on effects already observed to increase the ability to create individualized care over time.